Citizens JMP raised the firm’s price target on Nuvation Bio (NUVB) to $8 from $6 and keeps an Outperform rating on the shares. Nuvation Bio reported Q4 financial results and highlighted 204 new Ibtrozi starts in Q3, the analyst tells investors in a research note. The launch trajectory is exceeding expectations and is already outpacing ROS1 launches in recent memory, Citizens says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: